米国の先端巨大症治療市場規模、シェア、動向分析レポート：薬剤クラス別、流通チャネル別、セグメント別予測、2025年～2033年

米国の先端巨大症治療市場サマリー

米国の先端巨大症治療市場規模は2024年に5億7,130万米ドルと推計され、2033年には9億7,720万米ドルに達すると予測され、2025年から2033年までのCAGRは6.2%で成長すると予測されます。これは、MRIやIGF-1検査などの診断ツールの進歩、認知度の向上、疾患の症状に対する理解の深まりと相まって、先端巨大症の有病率の上昇と早期診断が進んだことに起因しています。

診断の技術的進歩と個別化治療レジメンの採用は、早期発見とアドヒアランスに役立つと期待されます。強力なヘルスケア・インフラ、保険サポート、集学的ケアチームが市場拡大をさらに後押しすると予想されます。

さらに、新しいソマトスタチン類似体、成長ホルモン受容体拮抗薬、個別化治療などの治療オプションの進歩は、有効性の向上と副作用の軽減をもたらします。これらの技術革新は患者の転帰を向上させ、治療プールを拡大するため、市場の需要を煽り、研究開発へのさらなる投資を促します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の先端巨大症治療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連市場見通し
• 業界バリューチェーン分析
• 規制の枠組み
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 業界の課題
  • 業界の機会
• 業界分析ツール
  • ポーターのファイブフォース分析
• 市場参入戦略

第4章 消費者行動分析

• 人口統計分析
• 消費者の動向と嗜好
• 購入決定に影響を与える要因
• 消費者向け医薬品クラスの採用
• 観察と推奨事項

第5章 米国の先端巨大症治療市場：薬剤クラスの推定・動向分析

• 米国の先端巨大症治療市場の薬剤クラス：主なポイント
• 薬剤クラスの変動分析と市場シェア、2024年と2033年
• 薬剤クラス別、2021年から2033年
  • ソマトスタチン類似体（SSA）
  • 成長ホルモン受容体拮抗薬（GHRA）
  • ドーパミン作動薬
  • その他の薬剤の種類（併用療法、パイプライン薬剤）

第6章 米国の先端巨大症治療市場：流通チャネルの推定・動向分析

• 米国の先端巨大症治療市場の流通チャネル：主なポイント
• 流通チャネル変動分析と市場シェア、2024年と2033年
• 流通チャネル別、2021～2033年
  • 病院薬局
  • 小売薬局
  • その他

第7章 米国の先端巨大症治療市場-競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業ヒートマップ/ポジショニング分析
• 戦略マッピング
• 企業プロファイル
  • Novartis AG
  • Ipsen Pharma
  • Sun Pharmaceutical Industries Ltd
  • Chiasma, Inc.
  • Crinetics Pharmaceuticals
  • WOCKHARDT
  • Pfizer Inc.
  • Ionis Pharmaceuticals, Inc.
  • Teva Pharmaceuticals

List of Tables

• Table 1. U.S. Acromegaly Treatment Market Estimates And Forecast, By Drug Class, 2021 - 2033 (USD Million)
• Table 2. U.S. Acromegaly Treatment Market Estimates And Forecast, By Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 U.S. Acromegaly Treatment Market Segmentation
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Primary Research Approaches
• Fig. 5 Primary Research Process
• Fig. 6 Market Snapshot
• Fig. 7 Drug Class Segment Snapshot
• Fig. 8 Distribution Channel Segment Snapshot
• Fig. 9 Competitive Landscape Snapshot
• Fig. 10 U.S. Acromegaly Treatment Market Value, 2024 (USD Million)
• Fig. 11 U.S. Acromegaly Treatment Market - Industry Value Chain Analysis
• Fig. 12 U.S. Acromegaly Treatment Market Dynamics
• Fig. 13 U.S. Acromegaly Treatment Market: Porter's Analysis
• Fig. 14 U.S. Acromegaly Treatment Market, By Drug Class: Key Takeaways
• Fig. 15 U.S. Acromegaly Treatment Market, By Drug Class: Market Share, 2024 & 2033
• Fig. 16 Somatostatin Analogues (SSAs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig. 17 Growth Hormone Receptor Antagonists (GHRAs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig. 18 Dopamine Agonists Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig. 19 Other Drug Types (Combination Therapies, Pipeline Drugs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig. 20 U.S. Acromegaly Treatment Market, By Distribution Channel: Key Takeaways
• Fig. 21 U.S. Acromegaly Treatment Market, By Distribution Channel: Market Share, 2024 & 2033
• Fig. 22 Hospital Pharmacies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig. 23 Retail Pharmacies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig. 24 Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig. 25 Key Company Categorization
• Fig. 26 Strategic Framework

U.S. Acromegaly Treatment Market Summary

The U.S. acromegaly treatment market size was estimated at USD 571.3 million in 2024 and is projected to reach USD 977.2 million by 2033, growing at a CAGR of 6.2% from 2025 to 2033. This is attributed to the rising prevalence of acromegaly and earlier diagnoses, coupled with advancements in diagnostic tools such as MRI and IGF-1 tests, improved awareness, and a better understanding of the disease's symptoms.

Technological advances in diagnostics and the adoption of personalized treatment regimens are expected to help early detection and adherence. Strong healthcare infrastructure, insurance support, and multidisciplinary care teams are further expected to support market expansion.

Moreover, advances in treatment options, including newer somatostatin analogs, growth hormone receptor antagonists, and personalized therapies, offer improved efficacy and fewer side effects. These innovations enhance patient outcomes and expand the treatment pool, fueling market demand and encouraging further investment in research and development.

U.S. Acromegaly Treatment Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. acromegaly treatment market report based on drug class, and distribution channel:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Somatostatin Analogues (SSAs)
• Growth Hormone Receptor Antagonists (GHRAs)
• Dopamine Agonists
• Other Drug Types (Combination Therapies, Pipeline Drugs)
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources & Third-Party Perspectives
  • 1.3.4. Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Data Visualization
• 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Acromegaly Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related Market Outlook
• 3.2. Industry Value Chain Analysis
• 3.3. Regulatory Framework
• 3.4. Market Dynamics
  • 3.4.1. Market Driver Analysis
  • 3.4.2. Market Restraint Analysis
  • 3.4.3. Industry Challenges
  • 3.4.4. Industry Opportunities
• 3.5. Industry Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
• 3.6. Market Entry Strategies

Chapter 4. Consumer Behavior Analysis

• 4.1. Demographic Analysis
• 4.2. Consumer Trends and Preferences
• 4.3. Factors Affecting Buying Decision
• 4.4. Consumer Drug Class Adoption
• 4.5. Observations & Recommendations

Chapter 5. U.S. Acromegaly Treatment Market: Drug Class Estimates & Trend Analysis

• 5.1. U.S. Acromegaly Treatment Market Drug Class: Key Takeaways
• 5.2. Drug Class Movement Analysis & Market Share, 2024 & 2033
• 5.3. U.S. Acromegaly Treatment Market Estimates & Forecast, By Drug Class, 2021 To 2033 (USD Million)
  • 5.3.1. Somatostatin Analogues (SSAs)
    • 5.3.1.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
  • 5.3.2. Growth Hormone Receptor Antagonists (GHRAs)
    • 5.3.2.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
  • 5.3.3. Dopamine Agonists
    • 5.3.3.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
  • 5.3.4. Other Drug Types (Combination Therapies, Pipeline Drugs)
    • 5.3.4.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)

Chapter 6. U.S. Acromegaly Treatment Market: Distribution Channel Estimates & Trend Analysis

• 6.1. U.S. Acromegaly Treatment Market Distribution Channel: Key Takeaways
• 6.2. Distribution Channel Movement Analysis & Market Share, 2024 & 2033
• 6.3. U.S. Acromegaly Treatment Market Estimates & Forecast, By Distribution Channel, 2021 to 2033 (USD Million)
  • 6.3.1. Hospital Pharmacies
    • 6.3.1.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 6.3.2. Retail Pharmacies
    • 6.3.2.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 6.3.3. Others
    • 6.3.3.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)

Chapter 7. U.S. Acromegaly Treatment Market - Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Heat Map/ Positioning Analysis
• 7.3. Strategy Mapping
• 7.4. Company Profiles
  • 7.4.1. Novartis AG
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Ipsen Pharma
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Sun Pharmaceutical Industries Ltd
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Chiasma, Inc.
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Crinetics Pharmaceuticals
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. WOCKHARDT
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Pfizer Inc.
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Ionis Pharmaceuticals, Inc.
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Teva Pharmaceuticals
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives